Viking Therapeutics, Inc.
US ˙ NasdaqCM ˙ US92686J1060

SecurityVKTX / Viking Therapeutics, Inc.
InstitutionDimensional Fund Advisors Lp
Latest Disclosed Ownership542,516 shares
Latest Disclosed Value $ 17,653,471
Dimensional Fund Advisors Lp reports 18.05% increase in ownership of VKTX / Viking Therapeutics, Inc.

On May 7, 2026 - Dimensional Fund Advisors Lp filed a 13F-HR form disclosing ownership of 542,516 shares of Viking Therapeutics, Inc. (US:VKTX) valued at $17,653,471 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 459,575 shares of Viking Therapeutics, Inc.. This represents a change in shares of 18.05% during the quarter. The current value of the position is $15,434,580 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-07 2026-03-31 13F VIKING THERAPEUTICS COM 92686J106 542,516 82,941 18.05 17,653 9.19 0.0008
2026-02-12 2025-12-31 13F VIKING THERAPEUTICS COM 92686J106 459,575 -11,684 -2.48 16,168 30.55 0.0034
2025-11-12 2025-09-30 13F VIKING THERAPEUTICS COM 92686J106 471,259 235,189 99.63 12,385 97.99 0.0027
2025-08-12 2025-06-30 13F VIKING THERAPEUTICS COM 92686J106 236,070 236,070 6,256 0.0014
2025-05-13 2025-03-31 13F VIKING THERAPEUTICS COM 92686J106 0 -100,762 -100.00 0 -100.00
2025-02-13 2024-12-31 13F VIKING THERAPEUTICS COM 92686J106 100,762 -10,394 -9.35 4,055 -42.39 0.0010
2024-11-07 2024-09-30 13F VIKING THERAPEUTICS COM 92686J106 111,156 64,266 137.06 7,037 183.18 0.0017
2024-08-09 2024-06-30 13F VIKING THERAPEUTICS COM 92686J106 46,890 -262 -0.56 2,486 -35.72 0.0006
2024-05-10 2024-03-31 13F VIKING THERAPEUTICS COM 92686J106 47,152 -14,981 -24.11 3,866 234.14 0.0010
2024-02-07 2023-12-31 13F VIKING THERAPEUTICS COM 92686J106 62,133 -364,631 -85.44 1,157 -75.51 0.0003
2023-11-09 2023-09-30 13F VIKING THERAPEUTICS COM 92686J106 426,764 -107,568 -20.13 4,725 -45.42 0.0015
2023-08-09 2023-06-30 13F VIKING THERAPEUTICS COM 92686J106 534,332 0 0.00 8,658 -2.73 0.0028
2023-05-12 2023-03-31 13F VIKING THERAPEUTICS COM 92686J106 534,332 -314,395 -37.04 8,901 127,042.86 0.0030
2023-02-09 2022-12-31 13F VIKING THERAPEUTICS COM 92686J106 848,727 -65,236 -7.14 8 -99.72 0.0024
2022-11-10 2022-09-30 13F VIKING THERAPEUTICS COM 92686J106 913,963 -369,962 -28.81 2,486 -32.99 0.0010
2022-08-12 2022-06-30 13F VIKING THERAPEUTICS COM 92686J106 1,283,925 -91,560 -6.66 3,710 -10.08 0.0013
2022-05-13 2022-03-31 13F VIKING THERAPEUTICS COM 92686J106 1,375,485 312,377 29.38 4,126 -15.62 0.0013
2022-02-09 2021-12-31 13F VIKING THERAPEUTICS COM 92686J106 1,063,108 296,385 38.66 4,890 1.56 0.0015
2021-11-12 2021-09-30 13F VIKING THERAPEUTICS COM 92686J106 766,723 430,845 128.27 4,815 139.31 0.0016
2021-08-12 2021-06-30 13F VIKING THERAPEUTICS COM 92686J106 335,878 23,474 7.51 2,012 1.82 0.0006
2021-05-14 2021-03-31 13F VIKING THERAPEUTICS COM 92686J106 312,404 114,045 57.49 1,976 76.90 0.0007
2021-03-08 2020-12-31 13F/A-2 VIKING THERAPEUTICS COM 92686J106 198,359 -1,466 -0.73 1,117 -3.96 0.0004
2021-02-11 2020-12-31 13F VIKING THERAPEUTICS COM 92686J106 198,359 -1,466 1,117 403.4010
2020-11-12 2020-09-30 13F VIKING THERAPEUTICS COM 92686J106 199,825 7,452 3.87 1,163 -16.15 0.0005
2020-08-13 2020-06-30 13F VIKING THERAPEUTICS COM 92686J106 192,373 106,046 122.84 1,387 243.32 0.0006
2020-05-14 2020-03-31 13F VIKING THERAPEUTICS COM 92686J106 86,327 47,021 119.63 404 28.25 0.0002
2020-02-14 2019-12-31 13F VIKING THERAPEUTICS COM 92686J106 39,306 -172,742 -81.46 315 -82.10 0.0001
2019-08-13 2019-06-30 13F VIKING THERAPEUTICS COM 92686J106 212,048 0 0.00 1,760 -16.51 0.0007
2019-08-12 2019-03-31 13F/A-2 VIKING THERAPEUTICS COM 92686J106 212,048 18,800 9.73 2,108 42.63 0.0008
2019-05-10 2019-03-31 13F VIKING THERAPEUTICS COM 92686J106 212,048 18,800 2,108
2019-02-26 2018-12-31 13F/A-1 VIKING THERAPEUTICS COM 92686J106 193,248 193,248 1,478 0.0007
2019-02-13 2018-12-31 13F VIKING THERAPEUTICS COM 92686J106 193,248 1,478 0.0007
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.